bioMerieux (OTCMKTS:BMXMF) Stock Rated “Reduce” by Sell-Side Analysts

bioMerieux (OTCMKTS:BMXMF) has been assigned an average recommendation of “Reduce” from the six analysts that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have given a hold rating to the company.

Several equities research analysts have recently issued reports on the stock. Zacks Research raised shares of bioMerieux from a “strong sell” rating to a “hold” rating in a research report on Monday, September 28th. Morgan Stanley reiterated an “underweight” rating on shares of bioMerieux in a research note on Friday, September 11th. Piper Sandler initiated coverage on shares of bioMerieux in a research report on Thursday, June 11th. They issued a “neutral” rating for the company. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of bioMerieux in a report on Wednesday, June 17th.

bioMerieux Stock Performance

BMXMF stock opened at $87.75 on Thursday. The business’s 50-day moving average price is $83.86 and its two-hundred day moving average price is $86.47. bioMerieux has a 1-year low of $77.00 and a 1-year high of $132.52.

About bioMerieux

bioMérieux is a France-based healthcare company specializing in in vitro diagnostics. The company develops, manufactures and markets diagnostic systems, reagents and software used to detect infectious diseases, support antimicrobial therapy decisions and assist with disease management.

Its product portfolio includes solutions for microbiology, molecular biology, immunoassays and syndromic testing. bioMérieux’s systems are used by hospitals, clinical laboratories and healthcare providers, while its industrial applications serve the food, pharmaceutical and cosmetics industries by helping customers monitor contamination, quality and safety.

Founded in 1963 by Alain Mérieux, bioMérieux traces its heritage to the Mérieux family’s work in medical diagnostics.